2014-06-16
Ark Biosciences Licenses Novel Drug Candidate from Roche for Potential Treatment of RSV infection
SHANGHAI, CHINA- Ark Biosciences, a biotech startup company focusing on innovative drug discovery and development, today announced a licensing agreement for Roche's Respiratory Syncytial Virus (RSV) drug candidate AK0529. Th...
know more >